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multiple liner regression analysis. RESULTS: The mean utility scores (SD) were
0.75(0.19) for EQ-5D and 0.68(0.12) for SF-6D. Validity was demonstrated by the
moderate to strong correlation coefficients (range: 0.404-0.594, P0.001) for four of
the eight hypotheses in both EQ-5D and SF-6D. Therewere no serious ceiling effects
for EQ-5D and SF-6D but floor effects for EQ-5D were large. SF-6D showed a better
discriminative capacity (ES0.573-1.179) between groups with different SAP-spe-
cific health status than EQ-5D (ES0.385-0.851). RE showed that SF-6D (32.7-218.7%)
was more efficient than EQ-5D. The areas under ROC of them all exceeded 0.5
(0.661-0.814, P0.001). Poor agreement between themwas observedwith ICC (0.477,
P0.001) and Bland-Altman plot analysis. Multiple liner regression showed that
clinical variables significantly (P0.05) influenced differences in utility scores be-
tween EQ-5D and SF-6D. CONCLUSIONS: This study provides evidence that EQ-5D
and SF-6D are valid and sensitive preference-based HRQoL instruments in Chinese
SAP patients. SF-6D may be a more effective tool with lower flooring effect and
greater sensitivity. Further study is needed to compare other properties, such as
reliability and longitudinal response.
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OBJECTIVES: Previous studies have shown associations between isotertinoin treat-
ment and inflammatory bowel disease (IBD) and suspected that acne treatment
with isotertinoin carries an increased risk of developing IBD. The association be-
tween acne drug therapy and incidence of IBD with adjustment of potential con-
founders, however, remains unclear. This study evaluated the effects of drug ther-
apies on the development of IBD in acne patients. METHODS: A longitudinal
retrospective study was conducted using the 2003-2007 MarketScan Medicaid
Claims dataset representing 176,889 eligible patients with acne vulgaris. The Cox
proportional-hazard survival analysis was performed to obtain the hazard ratios
(HRs) of IBD development, adjusting age, race, sex, physician specialty, Charlson
Comorbidiy index (CCI), cumulative dosage of isotretinoin and acne drug
treatment.RESULTS:A total of 492 of the patients had an IBD occurrencewithin the
study period. Black patients had lower hazard of developing IBD than white pa-
tients (p0.01). Comparedwith adults, youths and childrenwere less likely to have
an IBD occurrence (all p0.01). Patients seen by dermatologists are associated with
a 51% higher hazard of developing IBD (p0.01). Patients whose acne was treated
with oral antibiotics, topical antibiotics, or topical glucocorticoids were less likely
to develop IBD (HRs0.45, 0.42, 0.51, respectively; all p0.05) compared with those
without these drugs. Patientswith a higher cumulative dosage of isotretinoin treat-
ment had an 87% lower hazard of developing IBD (HRs0.13; p0.05). A unit in-
crease in CCI was associated with a 17% higher hazard of IBD incidence (p0.01).
CONCLUSIONS:The likelihood of IBD occurrence in acne patients treatedwith drug
therapy variedwith age and race, consultationwith dermatologists, and acnemed-
ication. The higher cumulative dosage of isotretionin treatment was associated
with a lower risk of developing IBD. With adding confounding controls to the anal-
ysis, the relationship between isotretionin treatment and IBD development reveals
different results from previous studies.
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OBJECTIVES: The ethanolic extract of dried fruits of Phyllanthus emblica Linn. was
investigated for its gastroprotective effects in the patients with gastric ulcers.
METHODS: Finely ground dried fruit weighing 500g was soaked in one litre of
absolute alcohol for 24 hrs at room temperature with occasional shaking. Filtrate
was evaporated on rotary evaporator under reduced pressure at 40oC to a thick,
semi-solid mass. Phytochemical analysis was carried out for alkaloids, saponins,
anthraquinones, flavanoids and tannins. For in-vivo activity, thirty patients with
known gastric ulcers were randomly divided into three groups naming test, posi-
tive control and negative control group, respectively. 500 mg of dried residue of
Phyllanthus emblica in three divided doses, i.e. 166.6 mg in each capsule contain-
ing the sufficient amount of lactose to make the bulk of capsule up to 500 mg was
administered to test group for 14 days. The same coloured capsules filled with
lactose 500mgwere given to the patients of negative control group (placebo group)
for 14 days. Similarly, Omeprazole 40 mg/day was given to the patients of positive
control group for same time duration. Both questionnaire and endoscopic investi-
gation based procedures were adopted to investigate the effects in three groups.
RESULTS: Phytochemical screening of plant confirmed the presence of alkaloids,
anthraquinones, saponins, sterols, terpenes, flavanoids and tannins. Patients in
test group reported significant reduction (p0.05) in intensity and duration of
stomach pain especially, at night when compared with negative control group.
Positive control group, however, reported absolute reduction in complains associ-
ated with gastric ulcer. Endoscopic examination by expert gastroenterologist re-
ported significant healing of ulceration in positive control and test group,
respectively. CONCLUSIONS: The results of the study indicated that the ethanolic
extract of Phyllanthus emblica fruits have gastroprotective effects in diseased hu-
mans. These effects can be further enhanced by further fractionation of active
constitutes of plant material.
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OBJECTIVES: To evaluate the clinical outcome and H. pyloriinfection status by GLQI
and PCR, before and after the triple (CMO, CAO or LTC) treatment regimen.
METHODS: Salivary samples of 225 patients of acid peptic disease were used to
determine the infection status and GLQI score before and after treatment regimen.
Information regarding direct/indirect costs incurred, clinical outcome and side
effects of drugs were determined by interviewing the patient and validated
questionnaires. RESULTS: Infection status was determined by successful amplifi-
cation of 16s r RNA and Cag T genes Positive eradication rate was 72.7% in males
and 70% in females in CMO treated, 88.13% in males and 87.5% in females in CAO
treated and 84.44% in males and 96.67% in females in LTC treated patients. The
highest improvement in the GLQI score after the treatment regimen was visible in
the LTC treated groupwith a change of 65.39, followed byCAO treated patientswith
a change of 49.73 and CMO treated patients with an improvement of 32.18. The
average cost effectiveness ratio was found to be best in the CAO treatment regimen
with a ratio of 9.43 followed by LTC treatment regimen with a ratio of 11.74 and
CMOwith a ratio of 49.13. Side effects like diarrhea, nausea, bad taste andmetallic
taste were significantly enhanced in CMO (P  0.001) when compared to CAO and
LTC treatment regimens. CONCLUSIONS: The present investigation suggests that
LTC has better efficacy and safety profile, but CAO is most cost effective amongst
the three treatment regimens. PCR assay can be scaled up for hospitals or clinics as
a cost effective non invasive diagnostic test.
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OBJECTIVES: To evaluate the use of a harmonic device, compared to mono- and
bi-polar electrosurgical dissection, in the laparoscopic removal of the gallbladder.
METHODS: A systematic review of the literature (via EMBASE and Medline data-
bases) initially identified 832 publications. Based on a priori defined eligibility cri-
teria, 10 randomised controlled trials were included in the final analysis. RESULTS:
Meta-analysis of the included studies showed that mean operating time was 17.0
minutes shorter (95%CI: 7.5, 26.6) in the harmonic scalpel group. Use of the har-
monic scalpel was associated with a 7% reduction in the overall risk of complica-
tions and a 25% reduction in the risk of gallbladder perforation, compared to the
electrocauterisation group. Four studies measured subjective post-operative pain
using a 10-point visual analog scale, where a patient would rate their peak pain
from 0 (no pain at all) to 10 (worst pain imaginable) at prescribed time points during
follow-up. Patients who underwent the harmonic procedure rated their post-oper-
ative pain significantly lower than those patients who underwent electrosurgery
(mean difference [95%CI], points: 1.1 [1.5, 0.7]; P  0.0001). CONCLUSIONS:
Despite heterogeneity amongst the trials, the laparoscopic cholecystecomy proce-
dure performed with a harmonic scalpel appears to offer a number of advantages
over conventional mono- and bi-polar electrosurgery. These include a shorter op-
erating time, lower rate of complication, andmilder post-operative pain. In partic-
ular, the risk of gallbladder perforation was 25% lower in those patients who re-
ceived the harmonic intervention. Gallbladder perforation can lead to serious post-
operative infection, particularly if bile enters the operative cavity. As such,
minimising these events would likely reduce the average length of hospitalisation
as well as treatment costs associated with the procedure. This evidence supports
the use of the harmonic scalpel over conventional electrocautery devices in lapa-
roscopic cholecystectomy.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gas-
trointestinal disorder with continuous nuisance bowel symptoms leading to long-
term disturbances to patients. The disease burden of long-term IBS, however, is
generally neglected in Taiwan. This study aimed to evaluate medical and drug
utilization for IBS outpatients receiving long-term medical treatments in Taiwan.
METHODS: This cross-sectional study was conducted from 2004 to 2008 using a
Longitudinal Health Insurance Database constituting of amillion beneficiaries ran-
domly sampled in 2005. Adult IBS outpatients’ medical claims and prescriptions
data were extracted and medication possession ratio (MPR) was calculated based
on anti-IBS prescriptions (i.e. anti-propulsive, anti-spasmodics, propulsive, anti-
depressive agents and laxatives). Patients whose accumulated prescription dura-
tion for more than 90 days and MPR80% were included as study cohort and their
medical and drug utilization were assessed. Monthly trends of medical and drug
utilization were analyzed by simple linear regression and stratified by gastroenter-
ology specialists and tiers of medical facilities. RESULTS: Only 1451 (3.5%) patients
were included, but this cohort (mean age 60.816.7 years; 54.0%male) contributed
to 20913 visits, 20.3%medical cost and 70.5% drug cost of the 40890 IBS outpatients.
Number of outpatient visits and total medical cost in study cohort significantly
increased over time (p0.01), particularly in regional hospitals. Number of visits to
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non-gastroenterology (10471; 50.1%) and gastroenterology specialists were similar,
but monthly trend of gastroenterology visits significantly increased (p0.001) in
different tiers of medical facilities. Antispasmodics (13904; 41.0%) and laxatives
(9240; 27.2%) were the most frequently prescribed and monthly consumptions of
antipropulsive, antispasmodics and propulsive significantly increased (p0.001)
over time. CONCLUSIONS: A small cohort of outpatients receiving long-term IBS
treatments contributed to 20% of all IBS outpatient expenditure. As their medical
utilization and cost are substantially increasing, further economic evaluation is
needed to inform resource allocation decisions in the future.
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OBJECTIVES: To examine the influence of 5-ASA adherence rates on total annual
direct costs in UC patients using a budget impact model. METHODS: This model
assessed health care costs and utilization (US payer’s perspective, 1-year horizon)
in patients 18 years with newly diagnosed or relapsing mild-to-moderate UC
taking one of the following treatments: Colazal®, Pentasa®, Asacol®, or Lialda®/
Mezavant®. The default health plan share (model base case) was based on the
average market share of 5-ASA formulations from June 2009 to May 2010. Adher-
ence rates andmean days of therapy were based on published claims data; relapse
rates were calculated for adherent patients (having a medication possession ratio
[MPR] 0.8) and nonadherent patients (MPR 0.8). All-cause direct costs were ob-
tained from published literature and converted to 2010 US dollars using the Con-
sumer Price Index. RESULTS: Total annual cost of care for patients on Lialda/Meza-
vant ($12,771) was the lowest of the 5-ASA therapies: Asacol, $13,098; Colazal,
$13,423; Pentasa, $14,139. Patients on Lialda/Mezavant also had the lowest inpa-
tient, emergency room, and office visit expenses. Although pharmacy costs were
higher for Lialda/Mezavant ($2801) compared with Asacol ($2669; the lowest phar-
macy cost of examined 5-ASAs), this incremental cost increase was offset by the
lower costs of hospital care for Lialda/Mezavant patients. Assuming a UC preva-
lence of 0.23%, a health plan with 1 million participants could save $419,565 if all
patients on Asacol switched to Lialda/Mezavant. Results of sensitivity analyses
revealed that Lialda/Mezavant adherence rate and inpatient costs for nonadherent
patients were the most influential variables impacting total annual health plan
cost savings. CONCLUSIONS: Lower inpatient health care costs were primarily
driven by decreases in relapse frequency associated with higher treatment adher-
ence rates. Therefore, optimal savings for health plansmay result from inclusion of
medications on formularies based on therapeutic value (including improved ad-
herence) rather than pharmacy costs.
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OBJECTIVES: A cost-effectiveness analysis on two vaccination programs against
rotavirus in Guangzhou, Chinawas conducted for two purposes: 1) a test case in the
context of urban areas to enrich the knowledge of national health policymakers in
determining the inclusion of these vaccination programs in the Chinese Expanded
Programme on Immunization, and 2) the findings may inform the city authorities
to include the vaccines in local immunization plans.METHODS: The two interven-
tions under evaluation (through the incremental cost-effectiveness ratio [ICER]) are
Lanzhou lamb vaccine and Rotarix. Major costs include those associated with vac-
cination (prices of vaccines, program costs of implementation, and vaccine wast-
age) and associated with diarrhea (direct medical costs: outpatient visit and hos-
pitalization; indirect costs: transportation and parents’ loss of wage). Effects were
assessed in terms of the number of deaths averted and the number of disability
adjusted life years (DALYs) averted. Epidemiological and other parameters are also
included. Additionally, 1- and 2-way sensitivity analyses were performed to assess
the uncertainty of the base case analysis. RESULTS: The ICER of the Lanzhou lamb
vaccine is more than $135,000 per death averted and $4146.16 per DALY averted;
the ICER of Rotarix is more than $1.2 million per death averted and $36807.29 per
DALY averted. Uncertainty analyses indicate that disease prevalence and the price
and efficacy of Rotarix are most influential in determining ICERs. Cost-effective-
ness with respect to these leading influential factors was evaluated.
CONCLUSIONS: In terms of DALYs averted with respect to the per capita GDP, the
Lanzhou lamb vaccine is very cost-effective (ICER  per capita GDP) and Rotarix
cost-effective (ICER  3 times per capita GDP). Two-way sensitivity analyses may
also suggest potential competitive pricing strategy for Rotarix in terms of cost-
effectiveness. Limitations and generalizability of this study are discussed along
with directions for future research.
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OBJECTIVES: This article presents the methodology and results of the phar-
macoeconomic analysis of the MagnexMetronidazole against the combination
therapies CefuroximeMetronidazole and CeftriaxoneMetronidazoleAmi-
kacin in the treatment of Gastrointestinal surgeries. METHODS: This prospec-
tive study was conducted at a tertiary care teaching hospital in India on subjects
randomly, MagnexMetronidazole was compared with the combination of two
groups CefuroximeMetronidazole or CeftriaxoneMetronidazoleAmikacin.
Pharmacoeconomic analysis was the primary objective and the study was con-
ducted in the successfully treated patients. All comparisons between treatment
groups were conducted using Analysis of Variance (ANOVA). All costs were
reported as Indian Rupee(INR) and actual unit costs collected in 2011 were use
for the analyses. [1 USD 49 INR]. RESULTS: In the successfully treated patients,
the average cost of treatment was numerically lower in the CeftriaxoneMet-
ronidazoleAmikacin combination. The analyses found that the average cost of
treatment for CeftriaxoneMetronidazoleAmikacin was INR 2989.86, Cefu-
roximeMetronidazole was INR 4191.92 and MagnexMetronidazole was INR
4458.04. Average cost per day for MagnexMetronidazole was INR 800.36,
CefuroximeMetronidazole was INR 744.42 and for CeftriaxoneMetro-
nidazoleAmikacin was INR 536.77. The Incremental Cost Effectiveness Ratio
between MagnexMetronidazole and CefuroximeMetronidazole was 5.37 and
between MagnexMetronidazole and CeftriaxoneMetronidazoleAmikacin
was 5.49. CONCLUSIONS: Prospective study was conducted in the teaching hos-
pital and average cost of treatment was the primary objective of the study. The
analyses found that average cost for MagnexMetronidazole was INR 4458.04,
CefuroximeMetronidazole was INR 4191.92 and CeftriaxoneMetronidazole
Amikacin was INR 2989.86. Average difference in cost between Magnex
Metronidazole and CefuroximeMetronidazole was 6.1% and between Mag-
nexMetronidazole and CeftriaxoneMetronidazole Amikacin was 49%.
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OBJECTIVES: To assess adherence to various oral formulations of 5-ASA for the
treatment of UC in a UK patient population.METHODS: Dispensed drug data from
10 million UK patients were examined in a retrospective analysis of adherence to
oral 5-ASA therapy. Patients receiving 2 dispensed prescriptions of 5-ASA be-
tween January 2008 andDecember 2009were eligible; thosemissing age and gender
data were excluded. Patients with a medication possession ratio (MPR) 90% were
considered adherent. Patients were grouped by 5-ASA formulation and dose; age-
and gender-adjusted adherence rates were calculated and compared using chi-
square, 1-sample t-tests, and odds ratio (OR) statistics. RESULTS: A total of 11,608
patients met inclusion criteria. Mean (SD) age was 51.7 (18.1) years, with an even
gender distribution. Overall, 30.9% of patients were adherent. More patients were
adherent to Mezavant (48.3%) compared with any other formulation: Asacol 800
mg, 40.7%; Mesren 400 mg, 36.7%; Pentasa 1,000 mg, 31.8%; Pentasa 500 mg, 29.7%;
Asacol 400 mg, 29.6%; Colazide 750 mg, 27.8% (all comparisons P 0.001). Mean
continuous adherence rates (MPR acrossmultiple refills), adjusted for age and gen-
der, were also higher for Mezavant (87%) compared with the other 5-ASAs: Asacol
800 mg, 82%; Pentasa 1,000 mg, 75%; Mesren 400 mg, 74%; Pentasa 500 mg, 69%;
Colazide 750 mg, 68%; and Asacol 400 mg, 66% (P 0.001 vs. other 5-ASAs). ORs for
likelihood of adherence revealed that, compared with Mezavant, patients on any
other 5-ASA were less likely to be adherent: Asacol 800 mg, 0.69; Pentasa 1,000 mg,
0.49; Mesren 400 mg, 0.47; Pentasa 500 mg, 0.42; Colazide 750 mg, 0.36; and Asacol
400 mg, 0.36 (all comparisons P 0.05). CONCLUSIONS: Overall adherence with
5-ASA therapies was low. Patients on once-daily Mezavant demonstrated greater
adherence compared with those on other 5-ASA formulations.
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OBJECTIVES: To assess adherence and persistence to oral mesalamine treatment
for UC using the Quebec provincial public health plan (RAMQ) database, and iden-
tify patient characteristics associated with adherence and persistence.METHODS:
A retrospective prescription claims analysis was conducted on a random sampling
of patients with UC from the RAMQ database. Eligible patients initiated mesala-
mine therapy between January 2005 and December 2009, and could not have a
diagnosis of Crohn’s disease. Adherence and persistence weremeasured for 1 year
after the index prescription; adherent patients were defined as having a medica-
tion possession ratio 0.8 and persistent patients had a subsequent claim for me-
salamine within 60 days of the prior claim. Odds of adherence and persistence
based upon patient characteristics (eg, gender, age, corticosteroid use, comorbidi-
ties) were modeled with logistic regression. RESULTS: Of 12,765 sampled database
patients, 1,681 met the inclusion criteria. Mean (SD) age was 55.3 (17.8) years and
43.4% were male; the most common comorbidities were hypertension (50.1%),
heart disease (41.3%), respiratory illness (33.9%) anddiabetes (32.7%). Overall, 27.7%
of patients were adherent at 12 months; 45.5% of patients were persistent at 12
months, a decrease from 66.7% at 3 months. Male gender and current use of corti-
costeroids were associated with higher adherence (odds ratio [OR] [95% confidence
A636 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
